| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Enzymes and Protein Markers |
1
Osteometer Biotech A/S, Osteopark, Herlev Hovedgade 207, 2730 Herlev, Denmark.
2
Center for Clinical and Basic Research, Ballerup Byvej
222, 2750 Ballerup, Denmark.
a Author for correspondence. Fax 45 4494 8940; e-mail Stephan_Christgau{at}osteobio.dk.
The Serum CrossLapsTM One Step ELISA is a sandwich assay
using two monoclonal antibodies specific for a ß-aspartate form of
the epitope EKAHDGGR derived from the carboxy-terminal telopeptide
region of type I collagen 
1-chain. Our objective was to
assess the clinical value of the Serum CrossLaps assay for monitoring
antiresorptive therapy in osteoporosis treatment. Samples obtained from
postmenopausal women treated with different doses of cyclic or
continuous hormone replacement therapy (HRT) with an estrogen analog
(tibolone) or with a bisphosphonate (ibandronate) were measured in the
Serum CrossLaps One Step ELISA at baseline and at various time points
during therapy. The corresponding urine samples were measured in the
urine CrossLapsTM ELISA and corrected for creatinine
excretion. The serum CrossLaps measurements and corresponding urinary
CrossLaps measurements were highly correlated (r >0.8
for all studies). The serum and urine CrossLaps measurements showed a
significant decrease among the women treated with clinically relevant
doses of either of the antiresorptive agents. Furthermore, the annual
percentage change in bone mineral density (BMD) correlated with the
measured changes in CrossLaps concentration. The serum CrossLaps assay
showed a specificity of 83–100% and a sensitivity of 59–83% for
assessing BMD changes. The corresponding values for the
creatinine-corrected urinary measurements were 83–92% specificity and
68–79% sensitivity. We conclude that performance of the convenient
Serum CrossLaps One Step ELISA is at least equivalent to that of the
urine text for follow up of antiresorptive treatment in osteoporosis.
Further studies are needed to optimize its use in this and other
clinical applications.
The following articles in journals at HighWire Press have cited this article:
|
|
 |
|
  F. R. SINGER and D. R. EYRE Using biochemical markers of bone turnover in clinical practice Cleveland Clinic Journal of Medicine, October 1, 2008; 75(10): 739 - 750. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Kelly, L. J. Suva, Y. Huang, V. MacLeod, H.-Q. Miao, R. C. Walker, and R. D. Sanderson Expression of Heparanase by Primary Breast Tumors Promotes Bone Resorption in the Absence of Detectable Bone Metastases Cancer Res., July 1, 2005; 65(13): 5778 - 5784. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Szulc, B. Claustrat, F. Marchand, and P. D. Delmas Increased Risk of Falls and Increased Bone Resorption in Elderly Men with Partial Androgen Deficiency: The MINOS Study J. Clin. Endocrinol. Metab., November 1, 2003; 88(11): 5240 - 5247. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. M. Crofton, N. Evans, and R. Stephen Serum CrossLaps Compared with Other Markers of Bone Turnover in Severely Malnourished Children before and after Refeeding Clin. Chem., January 1, 2003; 49(1): 192 - 195. [Full Text] [PDF]
|
|
|
|
 |
|
 H J Lehmann, U Mouritzen, S Christgau, P A C Cloos, and C Christiansen Effect of bisphosphonates on cartilage turnover assessed with a newly developed assay for collagen type II degradation products Ann Rheum Dis, June 1, 2002; 61(6): 530 - 533. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Alexandersen, B. J. Riis, J. A. Stakkestad, P. D. Delmas, and C. Christiansen Efficacy of Levormeloxifene in the Prevention of Postmenopausal Bone Loss and on the Lipid Profile Compared to Low Dose Hormone Replacement Therapy J. Clin. Endocrinol. Metab., February 1, 2001; 86(2): 755 - 760. [Abstract] [Full Text]
|
|
|
|
|
|
P. Szulc, F. Munoz, B. Claustrat, P. Garnero, F. Marchand, F. Duboeuf, and P. D. Delmas Bioavailable Estradiol May Be an Important Determinant of Osteoporosis in Men: The MINOS Study J. Clin. Endocrinol. Metab., January 1, 2001; 86(1): 192 - 199. [Abstract] [Full Text]
|
|
|
|
|
|
S. L. Greenspan, H. N. Rosen, and R. A. Parker Early Changes in Serum N-Telopeptide and C-Telopeptide Cross-Linked Collagen Type 1 Predict Long-Term Response to Alendronate Therapy in Elderly Women J. Clin. Endocrinol. Metab., October 1, 2000; 85(10): 3537 - 3540. [Abstract] [Full Text]
|
|
|
|
|
|
F. Pagani and M. Panteghini Biological Variation in Serum Type I Collagen Carboxy-Terminal Telopeptide Concentrations Clin. Chem., September 1, 2000; 46(9): 1439 - 1440. [Full Text] [PDF]
|
|
|
|
 |
|
 E.-E. Baulieu, G. Thomas, S. Legrain, N. Lahlou, M. Roger, B. Debuire, V. Faucounau, L. Girard, M.-P. Hervy, F. Latour, et al. Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: Contribution of the DHEAge Study to a sociobiomedical issue PNAS, April 11, 2000; 97(8): 4279 - 4284. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Christgau Circadian Variation in Serum CrossLaps Concentration Is Reduced in Fasting Individuals Clin. Chem., March 1, 2000; 46(3): 431 - 431. [Full Text] [PDF]
|
|
|
|
|
|
M. Wichers, E. Schmidt, F. Bidlingmaier, and D. Klingmuller Diurnal Rhythm of CrossLaps in Human Serum Clin. Chem., October 1, 1999; 45(10): 1858 - 1860. [Full Text] [PDF]
|
|
|
|
|
|
N. B. Watts Clinical Utility of Biochemical Markers of Bone Remodeling Clin. Chem., August 1, 1999; 45(8): 1359 - 1368. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. L. Traba, J. A. Calero, C. Mendez-Davila, C. Garcia-Moreno, and C. de la Piedra Different Behaviors of Serum and Urinary CrossLaps ELISA in the Assessment of Bone Resorption in Healthy Girls Clin. Chem., May 1, 1999; 45(5): 682 - 683. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
